Literature DB >> 22727919

Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma.

Askin Yildiz1, Hakan Yetimalar, Burcu Kasap, Cetin Aydin, Sumeyra Tatar, Ferit Soylu, Fatma Sebnem Yildiz.   

Abstract

OBJECTIVE: To evaluate whether a preoperative serum CA-125 level in patients with endometrial carcinoma can provide additional information in determining the stage of disease, and which cutoff value is optimal in this respect. STUDY
DESIGN: Retrospective chart review of 147 women with pathologically proven endometrial carcinoma who were treated between January 1999 and May 2009. The associations of preoperative CA-125 levels with the tumor stage, histologic type and grade, and the lymph node positivity were examined. To determine the values of cutoff point levels for serum tumor marker CA-125, the levels of 20 IU/ml and 35 IU/ml were compared.
RESULTS: High CA-125 levels significantly correlated with advanced stage and lymph node metastases. The ROC curve determined that the best cutoff value was 20 U/ml. The sensitivity and specificity of a CA-125 cutoff level of 20 U/ml were 75% and 69.51%, respectively, with a positive predictive value of 80.6% and negative predictive value of 84.9%.
CONCLUSION: The current study suggests that measurement of preoperative CA-125 is a clinically useful test in endometrial carcinoma patients. CA-125 appears to be a significant independent predictor of the advanced stage of the disease as well as lymph node metastases. The results complement a growing body of literature that supports the relationship between CA-125 level and stage of disease but more studies are needed to establish the appropriate cutoff level for serum CA-125 in this respect.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727919     DOI: 10.1016/j.ejogrb.2012.05.038

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  15 in total

1.  Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation.

Authors:  Emsal Pınar Topdağı Yılmaz; Yakup Kumtepe
Journal:  Eurasian J Med       Date:  2016-10

2.  Serum endocan levels in endometrial and ovarian cancers.

Authors:  Esra Laloglu; Yakup Kumtepe; Hulya Aksoy; Emsal Pınar Topdagi Yilmaz
Journal:  J Clin Lab Anal       Date:  2016-10-13       Impact factor: 2.352

3.  Role of spiral artery Doppler to screen type 2 endometrial cancer cases.

Authors:  Soner Düzgüner; Mehmet Burak Ozkan; Tuncay Küçüközkan; Enis Ozkaya; Fadıl Kara; Ipek Nur Balın; Vakkas Korkmaz; Mehmet Fatih Karslı; Burak Gültekin
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-03-01

4.  Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.

Authors:  Tao Jiang; Ling Huang; Shulan Zhang
Journal:  BMC Cancer       Date:  2015-05-12       Impact factor: 4.430

5.  HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival.

Authors:  Shi-Wen Jiang; Haibin Chen; Sean Dowdy; Alex Fu; John Attewell; Eleftheria Kalogera; Ronny Drapkin; Karl Podratz; Russell Broaddus; Jinping Li
Journal:  Int J Mol Sci       Date:  2013-11-18       Impact factor: 5.923

6.  Utility of Preoperative CA125 Assay in the Management Planning of Women Diagnosed with Uterine Cancer.

Authors:  N Povolotskaya; N Das; K Dhar; D Brinkmann; F Gardner; R Woolas
Journal:  Surg Res Pract       Date:  2014-02-27

7.  Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer.

Authors:  Nabil Abdalla; Robert Piórkowski; Paweł Stanirowski; Anna Słomka; Krzysztof Cendrowski; Włodzimierz Sawicki
Journal:  Prz Menopauzalny       Date:  2016-11-15

8.  Analysis of Risk Factors for Lymphatic Metastasis in Endometrial Carcinoma and Utility of Three-Dimensional Magnetic Resonance Imaging in Gynecology.

Authors:  Yasuhito Tanase; Junko Takahama; Ryuji Kawaguchi; Hiroshi Kobayashi
Journal:  World J Oncol       Date:  2018-06-26

9.  Role of less commonly agreed risk factors on disease recurrence in endometrial cancer: a propensity scorematched comparison.

Authors:  Hülya Ayık Aydın; Gülgün Erdoğan; Hatice Elif Pestereli; Tayup Şimşek
Journal:  Turk J Obstet Gynecol       Date:  2019-03-27

10.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.

Authors:  Nicoletta Colombo; Carien Creutzberg; Frederic Amant; Tjalling Bosse; Antonio González-Martín; Jonathan Ledermann; Christian Marth; Remi Nout; Denis Querleu; Mansoor Raza Mirza; Cristiana Sessa
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.